- Home
- GNTA vs RNXT Comparison
GNTA vs RNXT Comparison
Compare GNTA & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNTA | RNXT |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | Italy | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.0M | 36.4M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GNTA | RNXT |
|---|---|---|
| Price | $1.40 | $1.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.75 |
| AVG Volume (30 Days) | 100.3K | ★ 279.0K |
| Earning Date | 03-30-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $928,000.00 |
| Revenue This Year | N/A | $2,795.35 |
| Revenue Next Year | N/A | $272.69 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.28 | $0.70 |
| 52 Week High | $10.00 | $1.69 |
Technical Indicators
Market Signals| Indicator | GNTA | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 38.16 | 62.52 |
| Support Level | $1.35 | $0.84 |
| Resistance Level | $1.50 | $1.06 |
| Average True Range (ATR) | 0.15 | 0.09 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 23.53 | 69.33 |
Price Performance
Historical ComparisonAbout GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.